[1] 张明, 诸葛宇征, 邹晓平,等. 肝静脉压力梯度与肝硬化患者临床特征的相关性. 中华消化杂志, 2015, 35:530-533.
[2] 曹旬旬, 陆伦根. 肝静脉压力梯度在肝硬化门静脉高压症患者中的临床应用. 临床肝胆病杂志, 2013, 29:715-718.
[3] Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol, 2016, 65:692-699.
[4] 赵西太, 聂青和. 直接抗病毒药物治疗丙型肝炎的毒副作用、药物相互作用及安全性. 临床肝胆病杂志, 2017, 33:1067-1074.
[5] 屈慧新, 王玉泽, 王彩霞,等. 新型抗丙型肝炎病毒药索非布韦的研究进展. 沈阳药科大学学报, 2016, 33:334-338.
[6] Vorobioff JD, Groszmann RJ. Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. Ann Hepatol, 2013, 12:22-29.
[7] Lawitz E. Nucleotide Polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C. N Engl J Med, 2013, 368:34-44. |
